2021
Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH
Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. Journal Of Controlled Release 2021, 341: 457-474. PMID: 34856227, DOI: 10.1016/j.jconrel.2021.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntioxidantsHumansKupffer CellsMiceNitric OxideNon-alcoholic Fatty Liver DiseaseConceptsMannose receptor C type 1Treatment of NASHNonalcoholic steatohepatitisKupffer cellsBlood flowNO donorReactive oxygen speciesHepatic blood flowDevelopment of steatohepatitisNASH model miceC type 1Nitric oxide donorOxidative stress-associated pathologiesStress-associated pathologiesCombination therapyHepatoprotective effectModel miceLiver lobeOxide donorType 2Therapeutic potentialType 1Nitric oxidePathological phenotypesSpecific uptake
2018
Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery 2018, 25: 1055-1065. PMID: 29688069, PMCID: PMC6058604, DOI: 10.1080/10717544.2018.1464083.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsB7-H1 AntigenCell LineHepatitisHumansImmunologic FactorsInterferon alpha-2Interferon Type IInterferon-alphaInterleukin 1 Receptor Antagonist ProteinInterleukin-10Kupffer CellsLiverMaleMannoseMiceMice, Inbred C57BLMice, Inbred ICRRAW 264.7 CellsRecombinant ProteinsSerum AlbuminConceptsKupffer cellsImmunomodulatory actionsTypes of hepatitisHepato-protective effectsTreatment of hepatitisAlbumin fusion technologyIL-10Liver injuryPD-L1IL-1raImmunomodulatory effectsModel miceTherapeutic effectivenessSurvival rateIFNα2bRAW264.7 cellsHepatitisInterferon receptorMRNA levelsSignificant inductionConcanavalin AMenMiceConcept studyCells
2017
An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization
Park J, Shao M, Kim MY, Baik SK, Cho MY, Utsumi T, Satoh A, Ouyang X, Chung C, Iwakiri Y. An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology 2017, 65: 1720-1734. PMID: 28090670, PMCID: PMC5397326, DOI: 10.1002/hep.29051.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseasePositive Kupffer cellsKupffer cellsLiver injuryALD patientsLiver diseaseM1 polarizationKO miceM2 polarizationLieber-DeCarli ethanol liquid dietDisease severityM1/M2 polarizationKupffer cell polarizationEthanol liquid dietHepatic triglyceride levelsM2 macrophage polarizationHigher hepatic triglyceride levelsChronic ethanol feedingNew therapeutic targetsER stressAbsence of NogoM2 statusWT miceM1 activationTriglyceride levels
2016
Cellular distribution of injected PLGA-nanoparticles in the liver
Park JK, Utsumi T, Seo YE, Deng Y, Satoh A, Saltzman WM, Iwakiri Y. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine Nanotechnology Biology And Medicine 2016, 12: 1365-1374. PMID: 26961463, PMCID: PMC4889500, DOI: 10.1016/j.nano.2016.01.013.Peer-Reviewed Original ResearchConceptsPLGA nanoparticlesSafety of nanoparticlesUptake of nanoparticlesNanoparticle deliveryLiver sinusoidal endothelial cellsNanoparticle retentionNanoparticlesHepatic stellate cellsSinusoidal endothelial cellsKupffer cellsStellate cellsEndothelial cellsTarget cell typeCell typesClodronate liposomesLiver therapyLiver cellsMajor cellsLiverCell populationsCellular distributionLiposomesCellsHepatocytes
2015
Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase
Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clinical And Molecular Hepatology 2015, 21: 319-325. PMID: 26770919, PMCID: PMC4712158, DOI: 10.3350/cmh.2015.21.4.319.Books
2007
Decreased intrahepatic response to α1‐adrenergic agonists in lipopolysaccharide‐treated rats is located in the sinusoidal area and depends on Kupffer cell function
Lee C, Loureiro‐Silva M, Abraldes JG, Iwakiri Y, Haq O, Groszmann RJ. Decreased intrahepatic response to α1‐adrenergic agonists in lipopolysaccharide‐treated rats is located in the sinusoidal area and depends on Kupffer cell function. Journal Of Gastroenterology And Hepatology 2007, 22: 893-900. PMID: 17498219, DOI: 10.1111/j.1440-1746.2007.04922.x.Peer-Reviewed Original ResearchConceptsLipopolysaccharide-treated ratsKupffer cell functionVascular responsesAdrenergic agonistsKupffer cellsNormal liverSinusoidal areaNitric oxide synthase inhibitorCell functionOxide synthase inhibitorRole of KupfferVascular tone controlNitric oxide overproductionKrebs-Henseleit solutionNitric oxide productionΑ1-adrenergic agonistDose-response curveIntrahepatic responseMicrovascular abnormalitiesSecond doseEndotoxemic ratsLiver perfusionSynthase inhibitorMethoxamineGadolinium chloride